Latest Health News
WHO reviews 2025 as a year of health security action in Europe
WHO/Europe reports overlapping emergencies in 2025—armed conflict, infectious disease outbreaks, antimicrobial resistance and climate-driven events—and says it identified 35 new public health risks and responded to eight graded emergencies while analysing over 110,000 information pieces for early warnings.
WHO prequalifies first two rapid antigen COVID-19 tests
WHO announced prequalification of two rapid antigen detection tests for COVID-19, marking a step to improve global access to reliable diagnostics and pandemic preparedness.
WHO highlights major achievements and funding challenges at year-end
WHO Director-General Tedros summarized 2025 achievements amid challenges including funding cuts, while emphasizing pandemic agreement progress and the need for sustained resources for global health security.
U.S. signs landmark global health MOUs to strengthen epidemic preparedness
The United States signed new Memorandums of Understanding with several African countries to expand surveillance, reduce malaria deaths, and improve HIV diagnosis and treatment—pledging significant funding and capacity-building to meet 7-1-7 detection and response standards.
Sanofi to acquire Dynavax, expanding adult hepatitis B vaccine access
Sanofi announced acquisition of Dynavax to add a marketed adult hepatitis B vaccine and a phase 1/2 shingles candidate to its portfolio, aiming to address large unvaccinated adult populations and unmet needs in HBV prevention.
Major oncology advances reshape breast cancer treatment in 2025
2025 saw approvals and pivotal data for antibody‑drug conjugates and combinations (e.g., datopotamab deruxtecan approvals and DESTINY-Breast09 results) that improved outcomes across HR+, HER2+ and triple-negative breast cancer subtypes.
Notable neurology trials launched or progressed in 2025
Key neurology trials initiated in 2025 include studies of ozanimod de-escalation in MS, ublituximab for relapsing MS, and POLARIS-AD (AR1001) — a large phase 3 oral therapy trial for early Alzheimer’s disease with topline readout expected in 2026.
ScienceDaily reports major preclinical breakthroughs including Alzheimer’s and cancer findings
ScienceDaily’s health roundup highlights studies that reportedly reversed Alzheimer-like changes in mice, novel cancer-targeting nanoparticles, and advances in immune-oncology published across late 2025.
Civil society advocacy secures funds for epidemic prevention in Africa
Advocacy efforts helped secure over US$27 million (and growing) for epidemic prevention and strengthened country-level health security budgets, including Uganda’s US$15.4 million for preparedness and a dedicated Public Health Emergency Operations Centre line.
Genetics and genomic technologies marked as top science stories of 2025
Coverage of 2025’s top genetics stories emphasizes breakthroughs in sequencing, personalised CRISPR therapies, and other genomic advances shaping diagnostics and precision medicine.
Clearmind reports progress in non-hallucinogenic neuroplastogen therapy for alcohol use disorder
Clearmind Medicine announced positive Phase I/IIa safety and tolerability results and DSMB endorsement for CMND-100 (MEAI-based) in AUD trials with multinational site activations and continued enrollment.
Global focus on alcohol harms and NCDs in regional WHO action plans
WHO regional updates and calls to action highlighted alcohol’s health impact and the need for stronger regulation alongside efforts to strengthen NCD workforce capacity across regions including the Western Pacific.